BACKGROUND AND AIM: The aim of this study was to test whether there was an association between systemic levels of insulin like growth factor-1 (IGF-1), IGF-1 binding protein-3 (IGFBP3) and selected parameters of lipid metabolism depending on the lipid-lowering therapy. This work was conducted in patients described by us previously who had either highly probable, or documented, coronary artery disease, and controlled serum lipids with prolonged statin therapy. METHODS: The study was conducted among 140 patients undergoing coronary angiography. The following parameters were measured: LDL- and HDL-cholesterol levels, TG, TC, apoB-100, apoA1, Lp(a) and IGF-1 and IGFBP3, as well as the level of oxidation products of proteins and lipids. RESULTS AND CONCLUSIONS: In the group of patients with LDL target up to 100 mg/dl and statins use, as well as in the entire population, IGF-1 and IGFBP3 were associated with protein oxidation products and Lp(a). Additionally, in the whole studied group, IGF-1 was associated with TG and LDL. More differences were observed when we used multivariate analysis. Even then, IGF-1 and IGFBP3 in the group with LDL up to 100 mg/dL, as well as in the entire group, were associated with protein oxidation products, Lp(a) and with quantitative arteriosclerosis scale (Gensini score). These results seem to confirm our previous findings, wherein significantly higher levels of systemic IGF-1 were found in patients with advanced coronary atherosclerosis.
BACKGROUND AND AIM: The aim of this study was to test whether there was an association between systemic levels of insulin like growth factor-1 (IGF-1), IGF-1 binding protein-3 (IGFBP3) and selected parameters of lipid metabolism depending on the lipid-lowering therapy. This work was conducted in patients described by us previously who had either highly probable, or documented, coronary artery disease, and controlled serum lipids with prolonged statin therapy. METHODS: The study was conducted among 140 patients undergoing coronary angiography. The following parameters were measured: LDL- and HDL-cholesterol levels, TG, TC, apoB-100, apoA1, Lp(a) and IGF-1 and IGFBP3, as well as the level of oxidation products of proteins and lipids. RESULTS AND CONCLUSIONS: In the group of patients with LDL target up to 100 mg/dl and statins use, as well as in the entire population, IGF-1 and IGFBP3 were associated with protein oxidation products and Lp(a). Additionally, in the whole studied group, IGF-1 was associated with TG and LDL. More differences were observed when we used multivariate analysis. Even then, IGF-1 and IGFBP3 in the group with LDL up to 100 mg/dL, as well as in the entire group, were associated with protein oxidation products, Lp(a) and with quantitative arteriosclerosis scale (Gensini score). These results seem to confirm our previous findings, wherein significantly higher levels of systemic IGF-1 were found in patients with advanced coronary atherosclerosis.